Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.36B | 2.33B | 2.32B | 2.38B | 2.42B | 1.79B |
Gross Profit | 1.11B | 1.10B | 1.10B | 1.14B | 1.18B | 804.47M |
EBITDA | 41.11M | 66.72M | 35.84M | 136.66M | 190.36M | -59.66M |
Net Income | -24.25M | -18.89M | -16.83M | 71.92M | 114.85M | -56.03M |
Balance Sheet | ||||||
Total Assets | 1.42B | 1.34B | 1.33B | 1.46B | 1.56B | 1.59B |
Cash, Cash Equivalents and Short-Term Investments | 40.99M | 34.01M | 35.16M | 47.99M | 320.52M | 215.09M |
Total Debt | 452.86M | 485.09M | 522.94M | 580.43M | 632.64M | 734.04M |
Total Liabilities | 867.22M | 788.57M | 758.69M | 849.46M | 959.63M | 1.02B |
Stockholders Equity | 554.71M | 546.97M | 571.20M | 606.97M | 602.47M | 566.76M |
Cash Flow | ||||||
Free Cash Flow | 18.78M | 46.75M | 34.49M | -224.82M | 185.97M | 133.61M |
Operating Cash Flow | 79.22M | 87.89M | 94.80M | -164.88M | 239.87M | 157.74M |
Investing Cash Flow | -60.44M | -41.13M | -60.00M | -59.93M | -33.90M | -24.02M |
Financing Cash Flow | -23.04M | -47.00M | -47.58M | -45.53M | -101.17M | -3.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $608.50M | 9.79 | 9.69% | 2.63% | -6.42% | -19.27% | |
64 Neutral | $343.41M | 1,677.27 | 0.19% | ― | 1.64% | ― | |
63 Neutral | $248.97M | 6.85 | 34.74% | 1.90% | -2.37% | -16.40% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
50 Neutral | $326.02M | ― | -4.81% | ― | 2.66% | -4772.54% | |
46 Neutral | $156.28M | ― | -521.67% | ― | -12.08% | 93.16% | |
46 Neutral | $173.54M | 56.09 | ― | ― | -5.76% | -75.71% |
Genesco Inc. reported its fiscal 2026 second-quarter results, showing a 4% increase in net sales to $546 million compared to the previous year. The company experienced a 4% rise in comparable sales, driven by a 9% increase at Journeys. Despite a GAAP operating loss of $14.4 million, Genesco raised its full-year sales outlook, reflecting confidence in its strategic growth initiatives. The company continues to navigate challenges such as tariffs and a competitive market environment, while focusing on product elevation and customer experience to maintain momentum.
The most recent analyst rating on (GCO) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genesco stock, see the GCO Stock Forecast page.